NeRRe Therapeutics Company

NeoPhore, based in Cambridge, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Cancer neoantigens are known to stimulate the immune system and potentially be a weak spot in a tumour cell's defence mechanisms. The Company's approach targets genetic mechanisms that both clinical and lab studies suggest will promote neoantigen creation and diversity across numerous cancers. Using these insights, the Company aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.
Technology: Neurotech
Industry: Personalized Medicine
Headquarters: Stevenage, Herefordshire, United Kingdom
Founded Date: 2012
Employees Number: 11-50
Funding Status: Early Stage Venture

Visit Website
info@nerretherapeutics.com
Register and Claim Ownership